When considering the received author's materials Editorial Board and Editors-in-Chief of Cellular Therapy and Transplantation are guided by the following documents:
- Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals as approved by ICMJE – (International Committee of Medical Journal Editors)
- Rules for authors published on the official Journal website
- International ethical standards for the work of the editorial boards of biomedical journals developed by COPE
- The Declaration of Helsinki of the world Medical Association "Recommendations for physicians involved in biomedical research involving human subjects" (WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects)
- European Convention for the protection of vertebrate animals used for experimental and other scientific purposes (DIRECTIVE 2010/63/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 22 September 2010 on the protection of animals used for scientific purposes).
Cellular Therapy and Transplantation preferably publishes the results of studies conducted in accordance with the standard GCP (Good Clinical Practice).
Authors of manuscripts that do not meet our requirements receive a standard alert email without detailing the claims. If the manuscript is received again and again does not meet all the requirements for registration, it will be rejected without consideration.
After deciding on the proper format of the manuscript to all the requirements, the Editorial Board can decide on compliance or non-compliance of the manuscript to the profile of the journal.
All accepted research and review manuscripts will be sent to reviewers (general peer-review policy). Publication of the article is possible only after receiving positive reviews, but the positive review itself does not guarantee acceptance for publication. All the publication decisions are made by the editor-in-chief and/or editorial board only.
Authors who have decided that their research meets the profile of the Journal and agree with the policy of the Editorial Board should prepare a manuscript in accordance with all the appropriate journal's "requirements for manuscripts" and submit the manuscript to the editorial team on the Cellular Therapy and Transplantation journal's website.
Please prepare your submission to meet the following standards (this may be used as your checklist before you send us your manuscript):
• Article title in English;
• Author names with full names, abbreviated middle names and family names of all authors (example: Olga B. Ivanova, William M. P. Smith);
• Working affiliations;
• The corresponding author address, including postal address, phone No., Fax No. and E-mail address.
An abstract should be presented in English and in Russian (if possible), recommended length 1500 to 2000 characters. Keywords should be also provided (3 to 8 for each abstract), as well as a short ‘running title’ of fewer than 40 characters.
Original articles should contain standard sections, i.e., Introduction, Materials (Patients) and Methods, Results, Discussion/Conclusions, References, and Acknowledgements.
While an ideal length would be the equivalent of about 10 printed pages typed double-spaced [ca. 5000 words], you may exceed this length if your subject lends itself to it. You might also submit an article shorter than this since some issues are more appropriately dealt with in a concise style.
Any display items should be:
• accompanied by numbering and captions (providing an additional list of items might be helpful);
• in 300 dpi quality for the graphs in readable size (there is a complementary print edition of CTT).
Number the tables consecutively with Arabic numerals. Type each separately with titles making them self-explanatory. Define all abbreviations used in each table in a footnote key/legend beneath the table.
Abbreviations and symbols
Use only standard abbreviations. Write out all abbreviations in full at first use, with abbreviation following in parentheses, except for standard units of measures (e.g., mg, mL, dL). Avoid using abbreviations in the title of the paper.
• Give the list in plain text, please delete any automatic links to reference managing systems;
• Please list and number your references as they are cited in the manuscript. The cited works should be shown in the text by their numbers from the list of references [1,2 ....]. The articles published in other languages than English should be cited in English, with original language mentioned in parentheses at the end of reference (In Russian, or in German, etc.).;
• In the article, references should be cited by providing the name of the first authors et al. and the year of publication, if there are only two authors, both should be named; e.g. Friedenstein et al. 1974; Deans and Moseley 2000. Alternatively, you can use the referring numbers of your alphabetical reference list.
• We kindly ask to refer for articles, books, conference proceedings, electronic resources in formate accepted in PubMed (see under Citation).
• The articles with large team of authors should contain at least 6 first authors (… etc.).
• DOI indexes, if available, should follow every reference.
If appropriate, please include a section with the title “Acknowledgements” at the end of your article. In your Acknowledgements, please list the following, as applicable:
• Please give the names of colleagues who have contributed to your work but whose names do not appear among the authors. For contributors please list their full first name, abbreviate the second name and place the family name in the third position. After the name, please state the name and location of the institution in which they work (affiliation) and put this in parentheses. Do not use any titles (no Dr., PhD, etc.).
Example: “The authors wish to thank Olga P. Ivanova (Hematology Department, University of [town], [country]) for providing the cell line XYZ.”
• All sources of funding related to the work presented in the manuscript need to be acknowledged in this section. This concerns both institutional and corporate funding.
Example: “This work was supported by the Deutsche Forschungsgemeinschaft, grant No. XYZ.”
• Authors are expected to disclose any potential conflict of interest related to the submitted manuscript, particularly financial conflicts of interest. So, for this purpose, authors should disclose any commercial affiliations or consultancies, stock or equity interests, patent-licensing arrangements, or financial support received by a company which product is related to the study (e.g., a new drug tested described in the manuscript).
Example: “(Authors) A.I.K. is a consultant of ‘ABC drugs’, P.D.I. has received a personal grant from ‘D.E.F. Pharmaceuticals.”
Additional English language editing
Additional English language editing as well as translation of English abstracts into Russian (for non-native speakers of Russian) is available on acceptance of your submission for publication in CTT. The articles published in CTT are provided under the following license: Creative Commons Attribution 3.0 Unported, http://creativecommons.org/licenses/by/3.0/
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that the authors have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The confirmatory letter may be uploaded with your submission as a separate file.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
Hazards for Human or Animal Subjects
If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript. If the work involves the use of animal or human subjects, the authors should ensure that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. When reporting experiments on animals, authors have to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.
Research involving human embryos, gametes, and stem cells
Manuscripts that report experiments involving the use of human embryos and gametes, human embryonic stem cells and related biological materials, and clinical applications of stem cells must include confirmation that all experiments were performed in accordance with relevant guidelines and regulations (See also Research involving human participants and/or animals).
The manuscript should include an ethics statement identifying the institutional and/or national research ethics committee (including the name of the ethics committee) approving the experiments and describing any relevant details. Authors should confirm that informed consent was obtained from all recipients and/or donors of cells or tissues, where necessary, and describe the conditions of donation of biological materials for research, such as human embryos or gametes. Copies of approval and personal consent documents may be requested by the Cellular Therapy and Transplantation.
We encourage authors to follow the principles laid out in the 2016 ISSCR Guidelines for Stem Cell Research and Clinical Translation.